CN117617497A - Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly - Google Patents
Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly Download PDFInfo
- Publication number
- CN117617497A CN117617497A CN202311603423.8A CN202311603423A CN117617497A CN 117617497 A CN117617497 A CN 117617497A CN 202311603423 A CN202311603423 A CN 202311603423A CN 117617497 A CN117617497 A CN 117617497A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- leaching
- extraction process
- puerarin
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 84
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 81
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229940116269 uric acid Drugs 0.000 title claims abstract description 79
- 230000001603 reducing effect Effects 0.000 title claims abstract description 56
- 241000270708 Testudinidae Species 0.000 title claims abstract description 34
- 235000015110 jellies Nutrition 0.000 title claims abstract description 29
- 239000008274 jelly Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000002386 leaching Methods 0.000 claims abstract description 77
- 239000002904 solvent Substances 0.000 claims abstract description 36
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 26
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 26
- 150000001412 amines Chemical class 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 101710166469 Endoglucanase Proteins 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 4
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract description 56
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract description 56
- 230000000052 comparative effect Effects 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 201000005569 Gout Diseases 0.000 description 8
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 239000000419 plant extract Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010018634 Gouty Arthritis Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000219780 Pueraria Species 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- -1 alcohol amine Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Abstract
The invention discloses an extraction process for reducing uric acid components and application thereof in preparing tortoise jelly, and belongs to the technical field of biology. The extraction process provided by the invention comprises the following steps: mixing radix puerariae, leaching solvent and alkaline cellulase, and leaching at 50-70 ℃; the leaching solvent is a mixture of water, alcohol and organic amine; the pH of the leaching solvent is 8-9. The extraction process for uric acid reducing components provided by the invention can effectively improve the extraction efficiency of puerarin in the kudzuvine root, is simple, and is easy to realize and popularize. The invention also provides application of the extraction process in preparation of tortoise jelly.
Description
Technical Field
The invention relates to the technical field of biology, in particular to an extraction process for reducing uric acid components and application thereof in preparation of tortoise jelly.
Background
Uric acid is the final product of the metabolism of purine substances in vivo, and is produced by hypoxanthine and xanthine under the catalysis of xanthine oxidase, and peroxide free radicals are generated. Stable uric acid levels in the body involve a balance between uric acid production, absorption, metabolism and breakdown. Increased uric acid production or decreased uric acid excretion due to disturbed purine metabolism may lead to hyperuricemia. It is believed that a blood uric acid salt level of greater than or equal to 417. Mu. Mol/L may induce hyperuricemia or a range of other symptoms such as gouty arthritis and hyperuricemia nephropathy. Modern medicine has clarified that the onset of gout is directly related to hyperuricemia, and is a serious metabolic disease which endangers human health. Gouty arthritis is a tissue lesion and inflammatory reaction caused by urate deposition in joint capsules, synovium, cartilage, kidneys, subcutaneous tissues and other tissues due to the increase of uric acid in the body, and is mainly characterized by joint swelling, repeated pain attacks and joint flexion and extension disadvantages. Elevated blood uric acid is an important feature of gouty arthritis.
The main cause of the increase in uric acid is the change of dietary structure, and the intake of sugar, protein and fat is obviously increased. At present, common medicines for Western medicine treatment comprise nonsteroidal anti-inflammatory medicines, colchicine, glucocorticoid, probenecid, benzene-australine, allopurinol and the like, and most of the medicines are anti-inflammatory and analgesic medicines, and can quickly relieve pain, stop acute onset of gout, prevent gouty arthritis and gouty kidney stones from forming, but the medicines have serious side effects, such as damage to gastrointestinal tracts with different degrees, liver and kidney dysfunction in serious cases, bone marrow suppression, hepatocyte necrosis, neurotoxic reaction and the like after long-term administration. Researchers have therefore tried to explore traditional Chinese medicine ingredients to reduce uric acid accumulation.
The kudzuvine root has sweet, pungent and cool taste and has rich pharmacological effects, such as reducing vascular resistance, improving blood circulation of heart and brain, reducing heart rate fear, reducing oxygen consumption of cardiac muscle and the like. Clinically, the traditional Chinese medicine composition is commonly used for treating diarrhea, thirst, back pain, defervescence and other diseases caused by spleen deficiency and fever. The research shows that the kudzuvine root has the functions of reducing uric acid and resisting gout, and the action mechanism of the kudzuvine root can be related to improving liver and kidney injury, reducing serum uric acid and reducing the expression of urate transporter proteins in kidney tissues. Further, researches also find that the main component with uric acid reducing effect in the kudzuvine root is puerarin; in order to avoid the burden of other components in the kudzuvine root on the body of a patient, puerarin in the kudzuvine root needs to be extracted by a design method.
Aiming at puerarin, the traditional extraction method mainly comprises a water boiling method, a solvent leaching method, a percolation method and the like. In recent years, new materials and new technologies are continuously applied to traditional Chinese medicine extraction research, such as supercritical fluid extraction, ultrasonic extraction, semi-bionic extraction, cyclone extraction, enzymatic method and the like, and the technologies are still in research and development stages. At present, in actual production, the extraction of the kudzuvine root mostly adopts water extraction and alcohol extraction process route experimental design, and most adopts methods such as single factor design, orthogonal design, uniform design and the like, and optimal process conditions are optimized. Because the kudzu root raw materials in different areas and the experimental conditions are different in each experiment, the optimal technological parameters are greatly different. However, in either method, the extraction efficiency of pueraria is low, for example, the extraction efficiency of puerarin by a conventional percolation method is less than 1.5%, and the extraction efficiency of puerarin by a conventional water boiling method and a solvent leaching method is lower.
In conclusion, how to improve the extraction efficiency of puerarin in kudzuvine root is a key factor affecting the medical exertion of the uric acid reducing effect of puerarin.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems existing in the prior art. Therefore, the invention provides the extraction process for reducing uric acid content, which can effectively improve the extraction efficiency of puerarin, and is simple in extraction process and easy to realize and popularize.
The invention also provides application of the extraction process in preparing uric acid reducing products.
The invention also provides tortoise jelly, and the preparation raw materials of the tortoise jelly comprise uric acid reducing components (puerarin) extracted by the extraction process.
According to an embodiment of the first aspect of the present invention, there is provided an extraction process for uric acid lowering ingredients, the extraction process comprising: mixing radix puerariae, leaching solvent and alkaline cellulase, and leaching at 50-70 ℃;
the leaching solvent is a mixture of water, alcohol and organic amine; the pH of the leaching solvent is 8-9.
The extraction process provided by the embodiment of the invention has at least the following beneficial effects:
(1) The solubility of puerarin in water and alcohol is not very high, which is one factor limiting the extraction efficiency, and the invention adds organic amine into the leaching solvent, and the organic amine reacts with hydroxyl in puerarin to generate alcohol amine at pH of 8-9, so that the solubility of puerarin in the organic solvent is promoted, and the extraction efficiency of puerarin is further improved.
(2) Puerarin is a secondary metabolite of plants, which is present in the nuclear cell matrix inside cells, whereas the cells of pueraria are encapsulated in the cell wall, which is cellulose in composition. The alkaline cellulase adopted by the invention has higher activity under the pH condition of 8-9, and can decompose cell walls, thereby promoting puerarin in cells to be extracted; thereby improving the extraction efficiency of puerarin in the kudzuvine root.
According to some embodiments of the invention, the kudzuvine root may pass through an 80 mesh screen. Thereby increasing the contact area between the kudzuvine root and the leaching solvent and improving the leaching efficiency of uric acid reducing components (including puerarin).
According to some embodiments of the invention, the volume ratio of water to alcohol in the leaching solvent is 1:0.3-4. Considering that the types of the organic amine are different, the reaction product of the organic amine and puerarin is prone to be dissolved in water or alcohol, and the leaching solvent adopted by the invention comprises water and alcohol, so that the proportion of water to alcohol can be adjusted according to the needs in actual production, and the solubility of puerarin in the leaching solvent is improved.
According to some embodiments of the invention, the organic amine comprises at least one of methylamine, ethylamine, and triethylamine. The amount of organic amine added is determined by the pH of the leaching solvent.
According to some embodiments of the invention, a co-solvent is also included in the leaching solvent. Thereby further improving the efficiency of leaching uric acid components.
According to some embodiments of the invention, the co-solvent comprises at least one of PVP, lysine and nicotinamide.
According to some embodiments of the invention, the leaching solvent comprises 1-5 wt% of the co-solvent.
According to some embodiments of the invention, the mass to volume ratio of the kudzuvine root to the leaching solvent is 1g: 5-20 mL.
According to some embodiments of the invention, the alkaline cellulase accounts for 0.1-1% of the kudzuvine root by mass.
According to some embodiments of the invention, the number of leaches is 1-3.
According to some embodiments of the invention, the duration of a single leaching is 1-3 hours.
According to some embodiments of the invention, the leaching method comprises ultrasonic assisted reflux leaching.
According to some embodiments of the invention, the leaching uses ultrasonic waves with a power of 0.3W/cm 2 ～0.5W/cm 2 。
According to some embodiments of the invention, the ultrasonic waves used for the leaching have an ultrasonic frequency of 40kHz to 60kHz.
According to some embodiments of the invention, the extraction filtrate is obtained by sequentially filtering and standing precipitation after the extraction. The filtering can filter large-particle radix puerariae residues, and the standing precipitation can remove radix puerariae starch.
According to some embodiments of the invention, the filtering employs a mesh size of 200 mesh or more.
According to some embodiments of the invention, the length of time of the standing precipitation is 2-5 hours.
According to some embodiments of the invention, the extraction process further comprises, after the leaching, sequentially acidifying and extracting the resulting leaching filtrate.
According to some embodiments of the invention, the pH of the acidified leach liquor is in the range of 5 to 7.
According to some embodiments of the invention, the reagent used for the acidification is an aqueous acid solution. The solute of the aqueous acid solution comprises at least one of hydrochloric acid and oxalic acid. The pH of the acid aqueous solution is 2-4. The acid concentration is not very high, the puerarin and the organic amine can be promoted to form a compound which is converted into puerarin, and the puerarin performance can not be influenced by the excessive acidity.
According to some embodiments of the invention, the extractant used for the extraction comprises at least one of ethyl acetate and n-butanol. The extraction agents can selectively extract puerarin, and the separation ratio of the puerarin is high; the puerarin can be transferred from the leaching filtrate to the extractant by adopting the extractant, and the yield of the extraction step is higher.
According to some embodiments of the invention, the extracted O/a value is 1:2-4. Thereby, the uric acid lowering ingredient can be enriched in the extract phase.
According to some embodiments of the invention, the extracting comprises shaking and standing in sequence. The duration of the oscillation is 10-40 min. The standing time is 1-2 h.
According to some embodiments of the invention, the extraction process further comprises, prior to the acidification, performing a preliminary concentration of the leaching filtrate. The volume after preliminary concentration is 40-70% of the original volume. Therefore, the subsequent acidification and extraction amounts can be reduced, and the consumption of the extractant is saved; furthermore, the alcohol content in the leaching filtrate can be reduced to a certain extent, and mutual dissolution and emulsification between the leaching filtrate and the extractant in the subsequent extraction process are avoided.
According to some embodiments of the invention, the extraction process further comprises concentrating the resulting loaded organic phase after the extraction.
According to some embodiments of the invention, the concentrating comprises concentrating under reduced pressure.
According to some embodiments of the invention, the temperature of the concentration is 50-70 ℃.
According to some embodiments of the invention, the end point of the concentration is extractant-free.
According to some embodiments of the invention, the extraction process comprises the steps of:
s1, mixing kudzuvine root, leaching solvent and alkaline cellulase, and leaching;
the leaching solvent is a mixture of water, alcohol and organic amine, and the pH value is 8-9;
the leaching method comprises ultrasonic assisted reflux leaching;
s2, acidifying the leaching filtrate obtained in the step S1, and extracting an acidified product;
the extractant adopted by the extraction comprises at least one of ethyl acetate and n-butanol;
s3, concentrating the loaded organic phase obtained in the step S2; the concentrated product contains the uric acid reducing component, namely the puerarin.
According to an embodiment of the second aspect of the present invention, an application of the extraction process in preparing uric acid lowering products is provided.
The application adopts all the technical schemes of the extraction process of the embodiment, so that the method has at least all the beneficial effects brought by the technical schemes of the embodiment.
According to some embodiments of the invention, the uric acid reducing product is tortoise jelly. The tortoise jelly comprises uric acid reducing components extracted by the extraction process, so that the tortoise jelly not only has the effects of clearing heat and promoting diuresis and maintaining beauty and keeping young, but also can reduce uric acid and effectively relieve gout.
According to an embodiment of the third aspect of the present invention, there is provided tortoise jelly, wherein the raw materials for preparing the tortoise jelly include uric acid reducing components extracted by the extraction process.
The tortoise jelly adopts all the technical schemes of uric acid reducing components prepared by the extraction process of the embodiment, so that the tortoise jelly has at least all the beneficial effects brought by the technical schemes of the embodiment.
According to some embodiments of the invention, the tortoise jelly further comprises tortoise shell extract, other plant extracts and auxiliary agents.
According to some embodiments of the invention, the plant material of the other plant extract comprises at least one of cassia, hawthorn, red sage, astragalus, tuckahoe, plantain and burdock. Therefore, the other plant extracts can cooperate with uric acid reducing components extracted by the extraction process, and have better uric acid reducing effect.
According to some embodiments of the invention, the uric acid reducing component accounts for 0.1-1 wt% of the tortoise jelly.
According to some embodiments of the invention, the preparation method of the tortoise jelly comprises the following steps:
D1. decocting carapax et Plastrum Testudinis to obtain carapax et Plastrum Testudinis extract;
decocting plant materials to obtain the other plant extracts;
D2. mixing the carapax et Plastrum Testudinis extract and other plant extracts, heating and stirring to paste, and mixing with uric acid reducing component.
According to some embodiments of the invention, in step D1, the mass ratio of the tortoise shell to the plant material is 1:8-10.
According to some embodiments of the invention, in step D1, the duration of the boiling is 1-4 hours.
According to some embodiments of the invention, in step D1, the mass ratio of water to tortoise shell in the boiling is 5-10:1.
According to some embodiments of the invention, in step D1, the mass ratio of water to plant material is 8-10:1.
According to some embodiments of the invention, in step D1, the time period for the decoction is 10-40 min.
According to some embodiments of the invention, in step D2, the auxiliary agent comprises at least one of a flavouring agent and a stabilizer.
The term "about" as used herein, unless otherwise specified, means that the tolerance is within + -2%, for example, about 100 is actually 100 + -2%. Times.100.
Unless otherwise specified, the term "between … …" in the present invention includes the present number, for example "between 2 and 3" includes the end values of 2 and 3.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention.
In the description of the present invention, the descriptions of the terms "one embodiment," "some embodiments," "illustrative embodiments," "examples," "specific examples," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
The kudzuvine root used in the embodiment of the invention is collected and prepared according to Chinese pharmacopoeia (2015), and the specific collection place is selected from Shicheng.
Example 1
The example provides an extraction process for reducing uric acid components, which comprises the following specific steps:
s1, mixing kudzuvine root, leaching solvent and alkaline cellulase, and leaching; wherein,
the kudzuvine root is crushed 80 mesh screen lower material;
the leaching solvent is a mixture of water, alcohol and organic amine, and the pH value is 8.5; the volume ratio of the water to the alcohol is 1:2; the organic amine is triethylamine;
the leaching times are 3 times, after each leaching is finished, solid-liquid separation is carried out on the obtained mixed system by using a 200-mesh screen, and then the filtrate is kept stand for 4 hours, so as to obtain leaching filtrate of single leaching;
the alkaline cellulase is purchased from Beijing Soy Bao technology Co., ltd., CAS number is 9012-54-8, product number is C8270, and the dosage is 0.5% of the mass of the kudzuvine root raw material.
The leaching method is reflux leaching assisted by ultrasonic wave; the power of the ultrasonic wave used was 0.4W/cm 2 The frequency is 50kHz; the temperature is 60 ℃, and the duration of single leaching is 1h;
the leaching filtrates of the three leaches were combined and concentrated to 50% of the original volume. The concentration was carried out under reduced pressure at a temperature of 50 ℃.
S2, acidifying the concentrated leaching filtrate obtained in the step S1, and extracting an acidified product; wherein,
the reagent used for acidification is aqueous hydrochloric acid at ph=3.5.
The extractant adopted in the extraction is ethyl acetate; the O/A value is 1:3; the extraction includes shaking for 15min and then standing for 1.5h. Separating to obtain the loaded organic phase.
S3, concentrating the loaded organic phase obtained in the step S2; the obtained concentrated product contains uric acid reducing components including puerarin; wherein the concentration is reduced pressure concentration until the extractant is completely removed.
Example 2
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
in the step S1, the leaching solvent also comprises a cosolvent PVP, and the addition amount of PVP is 2% of the mass of the leaching solvent.
Example 3
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
ph=8 of the leaching solvent, volume ratio of water to alcohol is 1:0.5; the leaching temperature was 70 ℃.
Comparative example 1
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
ph=7 of the leaching solvent.
Comparative example 2
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
the temperature of leaching was 40 ℃.
Comparative example 3
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
the temperature of leaching was 80 ℃.
Comparative example 4
The embodiment provides an extraction process for reducing uric acid components, which is different from embodiment 1 in specific aspects:
the pH of the leaching solvent was adjusted directly with aqueous sodium hydroxide solution at ph=12 without the addition of an organic amine.
Application example 1
The tortoise jelly is prepared by the method, wherein the preparation raw materials comprise uric acid reducing components provided by the examples and the comparative examples; the method comprises the following specific steps:
D1. mixing carapax et Plastrum Testudinis (Brazilian tortoise) and water at a mass ratio of 1:8, and decocting for 3 hr to obtain carapax et Plastrum Testudinis extract;
mixing and decocting plant materials such as fructus crataegi and water at a mass ratio of 1:9 for 30min to obtain other plant extracts;
wherein the mass ratio of the tortoise shell to the hawthorn is 1:9.
D2. Mixing carapax et Plastrum Testudinis extract and other plant extracts, heating and stirring to paste, and mixing with uric acid lowering component; uric acid reducing components account for 0.5 percent of the tortoise jelly by mass.
Application example 2
The tortoise jelly is prepared in this example, and the specific differences from the application example 1 are that:
the preparation raw materials do not comprise uric acid reducing components prepared in examples and comparative examples.
Test example 1
The content of puerarin in uric acid reducing components obtained in examples and comparative examples was tested in this example, and the extraction efficiency of puerarin was calculated. Wherein, the content of puerarin is quantitatively detected by a high performance liquid chromatograph, and the chromatographic conditions are as follows:
chromatographic column: symmetry C18, 250mm x 4.6mm,5 μm;
mobile phase: methanol+36% acetic acid+water=25+3+72 (volume ratio);
flow rate: 0.60mL/min;
detection wavelength: 247nm;
sample injection volume: 10 mu L.
Drawing a standard curve: accurately weighing 20mg puerarin standard substance (accurate to 0.1 mg), dissolving in 70% methanol, and shaking to 100mL for use. At this time, the concentration of puerarin standard use solution was 200. Mu.g/mL. Sucking the above-mentioned use solution, using 70%The methanol is diluted into the following concentrations respectively: 5. Mu.g/mL, 10. Mu.g/mL, 20. Mu.g/mL, 30. Mu.g/mL, 50. Mu.g/mL standard use solution. The high performance liquid chromatograph is adopted to draw a standard graph, R, of a standard use solution for measuring puerarin, the puerarin concentration is taken as an abscissa (X axis) and the peak area is taken as an ordinate (Y axis) 2 ＞99.9％。
Preparation of sample solution: accurately weighing 0.500g (accurate to 0.0001 g) of a sample (uric acid reducing component), adding 5mL of 70% methanol, performing ultrasonic treatment in an ultrasonic cleaner for 25min, taking out, cooling to room temperature, fixing the volume to 10mL with 70% methanol, uniformly mixing, standing, taking supernatant, filtering with a 0.45 μm filter membrane, and performing quantitative analysis by using a high performance liquid chromatograph.
Calculating the ratio of the mass of the kudzuvine root in uric acid reducing components and the mass of the kudzuvine root raw material, and marking the ratio as the extraction efficiency of puerarin. The results of specific extraction efficiencies are shown in table 1.
Table 1 extraction efficiency of puerarin by the examples and comparative examples extraction process
| Example 1 | Example 2 | Example 3 | ||
| Extraction yield% | 3.2 | 3.5 | 3.0 | |
| Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | |
| Extraction yield% | 1.07 | 1.1 | 2.15 | 1.55 |
It is reported that the puerarin is extracted by ultrasonic extraction with 70% methanol aqueous solution, and the puerarin extraction rate is about 2.9% in the puerarin picked from Shicheng; compared with the traditional method, the extraction efficiency of puerarin in the kudzuvine root is obviously improved by adjusting the pH and the components of the leaching solvent and combining the synergy of alkaline cellulase.
As can be seen from comparative examples 1 and 2, if a certain amount of cosolvent is added into the leaching solvent, the leaching efficiency of puerarin can be further improved.
As can be seen from comparative examples 1 and 3, the activities of alkaline cellulases may not differ greatly at ph=8 and ph=8.5, but example 1 slightly increases the pH to facilitate the reaction of organic amine and puerarin, promote the dissolution in the leaching solvent, and further increase the leaching efficiency of puerarin in pueraria.
Comparative example 1 and comparative example 1 show that if the pH of the leaching solvent is lowered, on the one hand the activity of the alkaline cellulase is affected and on the other hand the content of organic amine used for pH adjustment is significantly lowered, thereby significantly inhibiting the reaction of organic amine and puerarin; overall, the extraction efficiency for puerarin is significantly reduced.
As is clear from comparative example 1 and comparative examples 2 to 3, lowering the temperature or raising the temperature affects the activity of alkaline cellulase; after the temperature is reduced, the reaction of the organic amine and puerarin can be influenced; but also promotes the leaching of puerarin and the reaction of puerarin and organic amine after the temperature is raised. Thus, the extraction efficiency of puerarin in comparative example 2 was significantly lowered, and the extraction efficiency of puerarin in comparative example 3 was only slightly lowered.
Comparative examples 1 and 4 show that if the organic amine is replaced with sodium hydroxide, the effect of strong base on enzyme and active ingredient in pueraria cells is unexpected, and in summary, has a negative effect on puerarin extraction efficiency.
According to the comparison and analysis, in the extraction process provided by the invention, the extraction efficiency of puerarin in the kudzuvine root is obviously improved through the synergistic effect between enzyme types and leaching solvent components.
Test example 2
The uric acid reducing effect of the tortoise jelly obtained in examples and comparative examples on uric acid was tested in this example and application examples 1 to 2 (pharmacological experiments on uric acid reducing effect of hyperuricemia mice).
1. Animal grouping and dosing program
Hypoxanthine is a precursor substance of uric acid in organism, and injection of hypoxanthine can accumulate uric acid, thereby inducing hyperuricemia; potassium oxazinate can inhibit uricase from decomposing uric acid, so that uric acid decomposition in a body is reduced, and uric acid level is continuously increased, thereby inducing hyperuricemia. The two can be combined to form a model which can obviously induce hyperuricemia and renal function injury.
SPF-grade Kunming male mice were randomly grouped into three major groups of 18 subgroups of 10 animals each. The three large groups are an experimental group, a control group and a blank group respectively, wherein 15 small groups are arranged in the experimental group, 2 small groups are arranged in the control group, and 1 small group is arranged in the blank group. After 4 days of adaptive feeding, the experiment is started after confirming that the animal has good health condition.
2. Grouping and experimental method
The blank control group is not treated and is fed normally. Except for blank groups, the other groups are subjected to continuous molding by adding hypoxanthine at a dosage of 500mg/kg, the corresponding groups of test drugs and positive control drugs are added at intervals of 30min in the first six days, the uric acid reducing components are extracted from each example or comparative example in the experimental group and are correspondingly named, and the injection is carried out according to an administration volume of 10mg (puerarin)/kg/d (the mass of tortoise jelly given by application example 2 is equal to that of tortoise jelly given by application example 1).
The control components are positive control group and negative control group, wherein the drug used as positive control drug is allopurinol. Allopurinol tablets were administered by gavage at a dose of 10 mg/kg/d. The negative control group was not treated except for feeding.
All mice fasted in the evening on the sixth day, and after the last administration of hypoxanthine for 30min on the seventh day, the corresponding group of drugs (reagents) were administered by intragastric administration at intervals of 20min with the exception of the blank control group and the negative control group, which were each of 300mg/kg of potassium oxazinate injected intraperitoneally.
1h after the intraperitoneal injection of the potassium oxazinate is finished, the orbit is used for taking blood, the blood is placed in a clean centrifuge tube, the blood is kept stand for 2h at room temperature, the blood is obtained after centrifugation for 10min at 3000rpm, and the blood is packaged in a 200 mu L centrifuge tube. Serum was assayed for blood uric acid content using uric acid kit and the results are shown in table 2. Results are all expressed as mean ± standard deviation. The mean and standard deviation of each group were calculated and t-tested using SPSS16.0 statistical software, respectively.
The results of the above tests are shown in table 2.
Table 2 uric acid reducing effects (part of) of uric acid reducing compositions obtained in examples and comparative examples and tortoise jelly obtained in application examples 1 to 2
Note that: *** represents p compared with the negative control group<0.001， # Representative is compared with blank group, p<0.1， ## Representative is compared with blank group, p<0.05。
Since the serum uric acid levels differ slightly between the examples, between the comparative examples, and between the corresponding application examples, only a few representative sets of results are listed in table 2.
Comparing the control group with the blank group, the animal modeling of the present invention was successful.
As is clear from comparison of the results of example 1 and comparative example 4, the effect of example 1 on reducing uric acid was better than that of comparative example 4, although the same puerarin equivalent was given, because the effect of reducing serum uric acid was better because the effect of reducing serum uric acid was smaller because the impurity content of the uric acid-reducing component obtained in example 1 was smaller, and the toxic and side effects on mice were also smaller, and the dosage was more accurate.
The comparison of the results of the example 1, the example 1-the application example 1 and the application example 2 shows that the tortoise jelly provided by the invention has a synergistic effect between other plant extracts and uric acid reducing components, and has obvious effect of reducing uric acid content in blood.
In summary, in the extraction process provided by the invention, a synergistic effect occurs between the steps and the parameters, so that the extraction efficiency and purity of puerarin in the obtained uric acid lowering ingredient are improved; furthermore, the uric acid reducing components and other preparation raw materials of the tortoise jelly have synergistic effect, so that the uric acid reducing effect is further improved.
While the embodiments of the present invention have been described in detail, the present invention is not limited to the above embodiments, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.
Claims (10)
1. An extraction process for reducing uric acid components is characterized by comprising the following steps: mixing radix puerariae, leaching solvent and alkaline cellulase, and leaching at 50-70 ℃;
the leaching solvent is a mixture of water, alcohol and organic amine; the pH of the leaching solvent is 8-9.
2. The extraction process according to claim 1, wherein the volume ratio of water to alcohol in the leaching solvent is 1:0.3-4.
3. The extraction process according to claim 1, wherein the mass to volume ratio of the kudzuvine root to the leaching solvent is 1g: 5-20 mL.
4. The extraction process according to claim 1, wherein the alkaline cellulase accounts for 0.1-1% of the kudzuvine root by mass.
5. The extraction process according to claim 1, wherein the number of leaches is 1-3; and/or, the duration of a single leaching is 1-3 h.
6. The extraction process of claim 1, wherein the method of leaching comprises ultrasonic assisted reflux leaching.
7. The extraction process according to any one of claims 1 to 6, further comprising, after said leaching, sequentially acidifying and extracting the obtained leaching filtrate; and/or the extractant used for the extraction comprises at least one of ethyl acetate and n-butanol.
8. Use of an extraction process according to any one of claims 1 to 7 for the preparation of uric acid lowering products.
9. The use according to claim 8, wherein the uric acid lowering product is tortoise jelly.
10. A tortoise jelly characterized in that the raw materials for preparing the tortoise jelly comprise uric acid reducing components extracted by the extraction process according to any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311603423.8A CN117617497A (en) | 2023-11-28 | 2023-11-28 | Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311603423.8A CN117617497A (en) | 2023-11-28 | 2023-11-28 | Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117617497A true CN117617497A (en) | 2024-03-01 |
Family
ID=90033284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311603423.8A Pending CN117617497A (en) | 2023-11-28 | 2023-11-28 | Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117617497A (en) |
-
2023
- 2023-11-28 CN CN202311603423.8A patent/CN117617497A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038720B (en) | Fuscoporia obliqua active ingredients capable of lowering blood sugar and preparation method and application of fuscoporia obliqua active ingredients | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN102283913B (en) | Radix aconiti carmichaeli extract and application thereof | |
| CN101953887B (en) | Medicinal composition for preventing and treating diabetic complications and preparation method thereof | |
| CN101591374B (en) | Steroid compound, preparation method thereof, medicinal composition containing compound and application of compounds | |
| CN117617497A (en) | Extraction process of uric acid reducing component and application of uric acid reducing component in preparation of tortoise jelly | |
| CN110559303A (en) | Refined bear gall powder for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases and atherosclerosis | |
| CN115227744B (en) | Lung-tonifying and blood-activating capsule and preparation method thereof | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| CN111905008A (en) | Compound hypoglycemic product and preparation method thereof | |
| CN112717078B (en) | Traditional Chinese medicine composition, preparation thereof, preparation method and application | |
| CN105726624A (en) | Pharmaceutical composition for treating diabetes | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN102151305A (en) | Shinyleaf yellowhorn extractive, extraction method thereof and user thereof | |
| CN108685964A (en) | The application of pilose gerbera herb extract and its active principle preparation method | |
| CN108578578A (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN1057300C (en) | Glucoside compound of catechine and preparation method and use thereof | |
| CN116354912B (en) | Compound and application thereof in serving as or preparing ABCG2 agonist | |
| CN116832114B (en) | Traditional Chinese medicine composition for improving quality of male ducks semen and preparation method and application thereof | |
| CN115317534B (en) | Application of myrtle extract in reducing blood sugar and treating diabetic nephropathy | |
| CN107811907A (en) | A kind of body lotion for promoting subcutaneous fat to decompose | |
| CN107281408A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof | |
| CN114652756A (en) | Seabuckthorn extract with gout preventing and treating effect and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |